
|Articles|August 1, 2004
Antiandrogen/castration may reduce death risk by 20%
New Orleans--Bicalutamide (Casodex), 50 mg, plus castration leads to an estimated 20% reduction in risk of prostate cancer death versus castration alone, according to results of a historical data analysis presented at the annual of the American Society of Clinical Oncology meeting here.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial launches of neuromodulation therapy for erectile dysfunction after radical prostatectomy
2
Andrea B. Apolo, MD, discusses survival gains with EV/pembrolizumab in bladder cancer
3
Rectal diazepam eases instillation of nadofaragene firadenovec in NMIBC
4
PROSTOX ultra launches on US market following new data presented at ASTRO 2025
5